The continuing non-availability of Anti-Hemophilic Factor IX in Jammu and Kashmir is a grim reminder of how administrative apathy can turn a medical crisis into a humanitarian catastrophe. For nearly a year, Hemophilia-B patients – many of them children – have been left without access to this critical, life-saving drug. Despite clear directions from the High Court to ensure an uninterrupted supply, the situation on the ground remains unchanged, exposing a shocking disregard for both law and human life. Hemophilia is not a condition that allows delay. Each bleeding episode, if untreated, can lead to severe joint deformities, organ damage, or even death within minutes. Yet, patients in the Union Territory are being forced to live each day in fear – not because medical science has failed them, but because the system has. The non-availability of Factor IX for almost a year, as reported from Government Medical College Jammu and associated hospitals, reflects not a logistical problem but a collapse of governance and accountability.
In this digital age, where data analytics can predict everything from rainfall to retail demand, it is incomprehensible that the administration cannot forecast the annual requirement of such a vital medicine. The truth appears to be far more disturbing – the drug was procured, but in insufficient quantities, revealing a deep flaw in planning and execution. When rules, procedures, and bureaucratic inertia stand in the way of life-saving treatment, they cease to serve the public good. Hospitals may claim helplessness in the absence of supply, but the real burden falls on helpless patients and their families. Those who can afford private care scramble to buy the expensive injections from outside, while the poor are left to suffer and die silently. Such selective access to survival makes a mockery of the very idea of a welfare state.
The government must treat this crisis with the urgency it demands. The Health and Medical Education Department, along with JKMSCL, must immediately procure and distribute Anti-Hemophilic Factor IX in adequate quantities. More importantly, a transparent, real-time inventory system should be developed to ensure uninterrupted availability throughout the year. Lives are at stake, and in such circumstances, rigid adherence to red tape is both cruel and indefensible. The administration must act now – before another patient bleeds out, waiting for a vial that never comes.
Follow our WhatsApp channel
